Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs
A close FDA committee vote to authorize molnupiravir indicates that mAbs could still be favored for Covid-19 when available.
By
Pharma Insights
Latest in
Pharma Insights
Astellas, Bayer and Mithra likely to turn up the heat in hot flashes market
Late-stage approaches to treat menopause-related hot flashes are expected to hit the market and may offer safer alternatives
By
Pfizer and Takeda deals put spotlight back on value-based pricing programs
Efforts to pay for a drug based on its value were limited by logistics, but recent deals for cancer drugs…
By
Vaxine to file for Australian approval of protein subunit Covid-19 vaccine
An Iran-staged trial shows SpikoGen exceeded the 60% efficacy bar in the primary endpoint of prevention of symptomatic disease.
By
Can DreamTec turn its bacteria-based oral Covid-19 vaccine into a reality?
DreamTec’s vaccine capsule contains bacterial spores studded with the SARS-CoV-2 receptor binding domain.
By
Schizophrenia drug landscape: a stagnant field on the cusp of change?
Several pipeline therapies could shake up the schizophrenia field, but their road through development is unlikely to be an easy…
By
Most of Latin America, Caribbean left behind in Merck’s oral Covid-19 antiviral deal
Many upper middle-income countries fall between the cracks after a recent landmark contract opened molnupiravir access to 105 countries.
By
Can Rigel’s bleeding disorder drug fostamatinib cross over into Covid-19?
Experts are optimistic of fostamatinib’s potential in hospitalised Covid-19 though they note available data is from a 59-patient trial.
By